<DOC>
	<DOC>NCT00002344</DOC>
	<brief_summary>To assess the dose proportionality of azithromycin concentrations and toleration when delivered in tablet formulation to HIV-infected patients. The need exists to further assess the antibacterial agent azithromycin at differing doses in an HIV-infected population.</brief_summary>
	<brief_title>A Study of Azithromycin in HIV-Infected Patients</brief_title>
	<detailed_description>The need exists to further assess the antibacterial agent azithromycin at differing doses in an HIV-infected population. Patients are randomized to receive azithromycin at 1 of 2 doses in a two-treatment, two-period, cross-over study. Dosing visits are separated by at least 14-day wash-out periods.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV seropositivity. CD4 count &lt;= 500 cells/mm3. NO active AIDS opportunistic infection. Exclusion Criteria Coexisting Condition: Patients with the following symptoms or conditions are excluded: Other active intercurrent illness. Any condition possibly affecting drug absorption (e.g., ulcers, gastrectomy, HIVassociated enteropathies. Signs or symptoms of severe illness that would preclude study participation. Known allergies to macrolide antibiotics. Patients with the following prior condition are excluded: Clinically important change in baseline status within 4 weeks prior to study entry. Prior Medication: Excluded: Investigational drugs including treatment IND drugs within 4 weeks prior to study entry. Known drug or alcohol dependence.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Azithromycin</keyword>
	<keyword>Bacterial Infections</keyword>
</DOC>